Tegaserod in women with dyspepsia

Phase 3, randomised, double-blind trial in dyspepsia comparing Tegaserod with Placebo (2 arms). Primary endpoints: Percent of days with satisfactory relief of dyspepsia at 6 weeks and Average severity score of post-prandial fullness, early satiety, and bloating at 6 weeks. Started Jan 2004; status: completed.